Chylopericardium

Article written and reviewed by Dr Luca Moretti

Chylopericardium is the accumulation of chyle within the pericardial cavity, resulting from an abnormal lymphatic communication, injury to lymphatic collectors, or an outflow obstruction that promotes reflux toward the pericardium. Chyle contains lipids absorbed from the intestine, proteins and immune cells; therefore, persistent leakage causes consequences that extend beyond the mechanical effect of the collection.

The presentation ranges from incidental findings and progressive dyspnea to cardiac tamponade. The composition of the fluid alone does not predict hemodynamic severity: the rate of accumulation, distribution and the ability of the sac to adapt are what matter. Drainage may relieve compression without correcting the lymphatic circuit responsible for recurrence.

Rarity limits therapeutic certainty. Reviews consist predominantly of published cases and small series, with selection of the most recognizable or complex presentations. Management should integrate characterization of the fluid, investigation of the cause, anatomic definition of lymphatic flow and nutritional protection, while avoiding automatic transfer to the pericardium of operative thresholds developed for chylothorax.

Etiology and organization of the lymphatic pathways

The thoracic duct carries a substantial portion of the body's lymph into the venous system, generally near the left jugulosubclavian junction. Its course includes variants, duplications and collateral connections that become relevant when planning interventions. Pericardial lymphatic collectors communicate with mediastinal and bronchomediastinal networks: a leak does not necessarily require transection of the main trunk, because it may arise from small branches, incompetent valves or retrograde flow through abnormal pathways.

The postoperative forms follow cardiac, esophageal, pulmonary or mediastinal surgery. Dissection, traction and thermal injury may interrupt lymphatic vessels even when the operative field does not appear directly adjacent to the duct. Fluid may appear after feeding is resumed, when intestinal fat transport increases, or may present later as a collection initially mistaken for a normal postoperative effusion. Thoracic trauma may act through direct rupture or pressure changes that damage connections and valves.

In secondary forms, lymphoma or another mediastinal neoplasm may obstruct outflow, infiltrate collectors or promote formation of collateral channels. The presence of chyle does not, however, prove that the pericardium is infiltrated by tumor cells. Thrombosis of major venous vessels, obstruction of lymphatic drainage, radiation-related sequelae and some infectious diseases may also contribute. Oncologic assessment should therefore consider both direct invasion and an obstructive mechanism external to the cavity.

An increase in central venous pressure reduces the pressure gradient for lymphatic drainage. Congenital heart diseases with particular circulations, right-sided dysfunction and other congestive conditions may render the lymphatic system insufficient, especially when structural variants or abnormalities coexist. Not every case of venous hypertension causes chylopericardium: the availability of collateral pathways and valve competence explain why patients with similar pressures can develop very different manifestations. This mechanism distinguishes reflux from a simple isolated surgical fistula.

Congenital lymphatic abnormalities include dilatations and dysplastic networks, sometimes within complex lymphatic disorders involving the pleura, lungs, bones or abdomen. An apparently isolated collection may be the first manifestation of a more extensive disorder. In children, associated heart disease, previous procedures and growth must be considered, because losses that are relatively modest in absolute terms may profoundly affect metabolic and immune balance.

The designation idiopathic requires a proportionate investigation that identifies no trauma, procedure, tumor, venous obstruction or recognizable lymphatic disease. It does not mean that no flow abnormality exists: lymphangiography may reveal pathological connections even after conventional thoracic studies are negative. In published series, the distribution of causes varies with patient age and origin; observed percentages do not provide a reliable estimate of prevalence in the general population.

Pathogenesis, pathophysiology and clinical presentation

The passage of chyle into the pericardium may depend on a direct leak or reflux into collectors unable to drain properly. The distinction has therapeutic consequences: closing a leak point may be sufficient for a localized lesion, whereas a network exposed to high pressure may continue to create other pathological drainage pathways. For this reason, the anatomic result of embolization must be interpreted together with venous function and the behavior of the entire lymphatic system.

Long-chain triglycerides absorbed from the intestine are transported mainly in chylomicrons through the lymph. The flow and appearance of the leak are therefore influenced by diet: milky fluid after meals may become less opaque during fasting without the fistula having healed. Fat restriction changes the output of the leak, but does not by itself prove anatomic closure. Subsequent refeeding may again reveal a defect that is still present.

The cardiocirculatory effect follows the relationship between pericardial pressure and volume. Slow accumulation allows considerable distension before pressure impairs filling; rapid increase, an already stiff cavity or a loculated distribution may cause compromise with smaller amounts. Echocardiography must therefore assess chambers and flows, not merely measure the effusion. Chylous origin does not protect against shock and does not justify waiting for nutritional therapy when perfusion is compromised.

Dyspnea is a common manifestation in symptomatic cases, accompanied by reduced exercise tolerance, chest heaviness, cough or fatigue. Typical pleuritic pain and fever are not required and, if prominent, warrant investigation for inflammation, infection or another complication. In slowly evolving cases, the examination may be minimally informative; in compressive presentations, venous congestion, tachycardia, pulsus paradoxus and signs of hypoperfusion appear, with variable expression depending on filling conditions.

Nutritional loss becomes particularly important during prolonged drainage. Proteins, calories, electrolytes and lymphocytes are lost in amounts that depend on output and duration; weight loss, hypoalbuminemia, impaired wound healing and susceptibility to infection may occur. Low albumin must also be interpreted in relation to inflammation, dilution and the underlying disease. An apparently compensated balance maintained by infusions does not eliminate the metabolic burden and risk associated with ongoing loss.

The concomitant presence of chylothorax, chylous ascites or peripheral edema points toward a broader lymphatic disorder or a venous component. The history should reconstruct the chronology of symptoms, procedures, diet and previous thrombotic events, relating them to studies already available. A mediastinal mass, lymphadenopathy or systemic symptoms suggest a specific etiologic pathway. The clinical picture must be reconsidered over time: a collection initially well tolerated may become dangerous during reaccumulation or loss of circulatory reserve.

Diagnosis of the fluid and etiologic definition

Echocardiography documents the site, amount and consequences of the effusion, but cannot determine its chylous composition with certainty. Turbidity and fine internal echoes are nonspecific findings. Biochemical diagnosis requires a sample obtained when drainage is clinically indicated or necessary to clarify a significant collection; patient stability determines timing and method. In cases with tamponade, sampling and treatment occur together without waiting for laboratory results to delay decompression.

A milky appearance is a clue, not sufficient proof. Pus, cellular debris and chronic cholesterol-rich collections may be turbid; chyle may instead be only mildly opaque during fasting, malnutrition or admixture with blood. Demonstration of chylomicrons by lipoprotein analysis, when available, is particularly useful in uncertain samples. The laboratory request should specify the suspicion, because a standard biochemical panel may not include the necessary characterization.

Classic descriptions of chylopericardium often show elevated triglycerides, sometimes above 500 mg/dL, a cholesterol-to-triglyceride ratio below one and lymphocyte predominance. These findings support the diagnosis, but the 500 mg/dL threshold is not a universal criterion capable of excluding it when the value is lower. Diet, metabolic status and dilution influence the result. Thresholds developed for pleural fluid should not be transferred mechanically to the pericardium.

Pseudochylopericardium, or cholesterol-rich effusion, belongs in the differential diagnosis of chronic collections. Crystal examination, lipid distribution and absence of chylomicrons help distinguish it from true chyle. Pericardial protein content should not be classified by applying Light's pleural criteria without caution. Cultures and cytology are selected according to the context: chylous fluid does not exclude concomitant infection, and negative cytology does not exclude an external neoplastic obstruction.

Chest CT with an appropriate protocol assesses masses, lymphadenopathy, pleural disease and venous obstruction; the extent of the study depends on the findings. When a lymphoproliferative disorder is suspected, flow cytometry and biopsy of the most informative target may complement cytology. Blood tests include complete blood count, renal and liver function, electrolytes and assessment of nutritional status. Testing for infection or autoimmunity should follow clinical evidence, avoiding indiscriminate low-pretest-probability panels.

Lymphangiography and lymphoscintigraphy address the question of the abnormal pathway. Intranodal techniques, CT after contrast opacification and, in expert centers, dynamic lymphatic MRI may show leaks, reflux or obstruction. A negative study does not exclude an intermittent defect or one not opacified by the access route used. The choice depends on the suspected anatomy and the possibility of treatment during the same procedure: before intervention, it is necessary to understand whether the duct is accessible and whether its closure will actually correct the mechanism.

Conservative treatment and metabolic support

The first decision concerns hemodynamic stability. In the presence of clinically significant compression, drainage cannot be replaced by diet, octreotide or lymphangiographic investigation. After decompression, whether a conservative trial is reasonable is assessed according to the cause, residual output and general condition. The strategy requires explicit goals: reduce the leak, maintain adequate nutritional intake and establish when failure to improve should prompt intervention on the lymphatic system.

Long-chain fat restriction aims to reduce chyle production. Medium-chain triglycerides are absorbed predominantly through the portal circulation and can provide energy while limiting lymphatic load. The diet must remain sufficiently caloric and protein-rich, with attention to essential fatty acids and fat-soluble vitamins if restriction is prolonged. A generically fat-free prescription without nutritional assessment may worsen the very problem it is intended to correct.

Parenteral nutrition has a role when the leak is substantial, enteral feeding does not achieve control, or a period of bowel rest is needed within specialist management. It is not a mandatory step in every stable case. Venous access, infectious and thrombotic risk, glucose and metabolic complications must be monitored; central thrombosis may itself impair lymphatic drainage. The indication is reassessed together with drainage trends and the possibility of resuming enteral feeding.

Octreotide is used in some cases to reduce splanchnic flow and lymph production, but evidence in chylopericardium is limited and protocols are not standardized. Dose, route and duration require specialist judgment, particularly in children. Response is not guaranteed; glucose, gastrointestinal tolerance and other adverse effects should be monitored. The drug is a possible adjunct and not a reason to prolong a major leak or defer treatment of a correctable lesion.

Etiologic therapy may be decisive when a neoplasm, venous obstruction or congestive condition exists. Treatment of the tumor may reduce pressure on lymphatic collectors; management of thrombosis and intravascular access must be coordinated with bleeding risk and pericardial procedures. In complex lymphatic disorders, any systemic therapies belong to dedicated pathways and should not be generalized to isolated forms. Anti-inflammatory drugs and colchicine do not correct a lymphatic leak in the absence of a separate indication.

Monitoring includes drain output, weight, fluid balance, electrolytes, proteins and hematologic parameters, as well as the residual collection. Output should be related to body size and metabolic condition. Published failure thresholds come from heterogeneous experience: no daily volume or duration has been universally validated for every case of chylopericardium. Persistently high output, compressive recurrence or nutritional deterioration require prompt reassessment, without rigidly waiting for a predetermined number of days.

Lymphatic interventions, surgery and drainage management

A pericardial catheter can control compression and quantify the leak, but drainage alone may become a continuous loss of nutrients if the source is not addressed. Removal requires joint assessment of output, imaging and diet; a decrease observed during complete fasting may be misleading. Reaccumulation after removal suggests persistence of the communication or pathological gradient and requires reconsideration of the pathway, not simply indefinite repetition of aspiration.

Lymphatic embolization uses access to selected collectors to interrupt the responsible flow. Lymphangiography may define the target and, in some leaks, may itself contribute to closure, but the result is not predictable. Transabdominal or retrograde access, embolic materials and selectivity depend on anatomy and center experience. A finding of diffuse reflux requires a different strategy from closure of a clearly demonstrated injured branch after surgery.

The largest evidence base for embolization concerns chylothorax and other thoracic leaks, whereas pericardial evidence consists mainly of case reports and small series. Results of pleural meta-analyses cannot be presented as chylopericardium-specific success probabilities. Inability to gain access, persistent collateral channels, recurrence and complications of opacification or embolization should be discussed. Careful selection may avoid major surgery, but does not justify delay when hemodynamic or metabolic control remains inadequate.

Thoracic duct ligation, often combined with a pericardial window, is an established option in persistent or recurrent cases. Thoracoscopic access may reduce invasiveness when anatomy permits. Low ligation near the diaphragm accounts for frequent more cranial branching; variants and collateral injuries may nevertheless require adaptation. The surgeon must integrate lymphangiographic findings, previous operations and the distribution of collections, especially when a chylous pleural effusion is also present.

A pericardial window reduces the risk of recurrent compression by providing a drainage route, but does not guarantee interruption of the lymphatic leak. Communication with the pleura may shift the problem if the source remains active. Therefore, the choice among an isolated window, combined ligation and endovascular treatment should be based on the mechanism and goal of the intervention. Extensive pericardiectomy is not routine treatment for simple chylopericardium; it becomes relevant only in selected circumstances, such as documented constriction.

After treatment, the functional outcome, not merely radiologic closure, must be verified. Resumption of feeding, sustained reduction in output and absence of reaccumulation provide complementary information. Recurrence may result from an untreated pathway, persistent venous obstruction or the underlying disease. Coordination among cardiology, thoracic surgery, interventional radiology and nutrition allows selection of the next step without restarting the entire diagnostic process each time.

Prognosis, complications and surveillance

The prognosis is generally favorable when a localized leak is corrected and the patient does not have severe systemic disease. It is different in neoplastic obstruction, diffuse lymphatic abnormalities or heart disease that maintains high venous pressures. Healing rates from surgical series reflect patient selection, technique and duration of follow-up; they should not become individual guarantees. Success includes suppression of the collection, nutritional recovery and maintenance of a tolerable lymphatic circulation.

Cardiac tamponade may be the first manifestation or may occur during a recurrence. After drainage, improvement in arterial pressure does not eliminate the need for surveillance, especially with large collections or in patients with ventricular dysfunction. Pericardial decompression syndrome, rare but potentially serious, requires recognition of respiratory or circulatory deterioration after evacuation. Catheter management should prevent obstruction, displacement and infection without prematurely stopping monitoring that is still needed.

Immune-nutritional depletion is a cumulative complication. Prolonged loss of lymphocytes and proteins, together with the underlying disease and invasive devices, may promote infection and delay recovery. Correction requires adequate intake and, above all, reduction of the leak, not merely restoration of laboratory values. In children, growth and development are assessed; in frail adults, muscle mass, independence and rehabilitation tolerance should be followed, as they may worsen before obvious weight changes occur.

Chronic inflammation and repeated procedures may be associated with thickening and, rarely, constrictive pericarditis. Persistent congestion after resolution of the fluid requires investigation for residual restriction, right-sided dysfunction or venous obstruction, conditions that cannot be distinguished by the appearance of the sac alone. Echocardiography with Doppler and complementary imaging are used according to the clinical question. The diagnosis of constriction does not automatically follow from the duration of the effusion or modest anatomic thickening.

Initial follow-up should document stability of the collection, normalization of fluid and metabolic balance, and tolerance of progressive dietary liberalization. Follow-up frequency and duration depend on treatment, cause and recurrence risk; no schedule is validated for all patients. New dyspnea, increased heart rate, reduced urine output, edema or general deterioration require earlier reassessment. Without a catheter, echocardiography has a central role in detecting reaccumulation that is initially minimally symptomatic.

Prevention of recurrence includes control of the responsible disease and documentation of the treated anatomy, which is useful for future procedures. Indefinite dietary restrictions are not justified when the leak has remained resolved; conversely, apparent healing during severely restricted nutrition should be verified gradually. In cases defined as idiopathic, a new collection or the appearance of systemic findings may require etiologic reassessment. The goal is durable recovery without unnecessarily maintaining catheters, deficiencies or treatments without demonstrated benefit.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Verma B et al. Clinical characteristics, evaluation and outcomes of chylopericardium: a systematic review. Heart. 2023;109(17):1281-1285.
5. Rochefort MM. Review of chylopericardium. Mediastinum. 2022;6:3.
6. Dib C et al. Chylopericardium in adults: A literature review over the past decade (1996–2006). Journal of Thoracic and Cardiovascular Surgery. 2008;136(3):650-656.
7. Itkin M, Chen EH. Thoracic Duct Embolization. Seminars in Interventional Radiology. 2011;28(2):261-266.
8. Kim PH, Tsauo J, Shin JH. Lymphatic Interventions for Chylothorax: A Systematic Review and Meta-Analysis. Journal of Vascular and Interventional Radiology. 2018;29(2):194-202.e4.
9. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
10. Ben-Horin S et al. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. American Journal of Medicine. 2005;118(6):636-640.
11. Saab J et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathology. 2017;125(2):128-137.
12. Sarode K et al. Pericardial Decompression Syndrome: A Comprehensive Review of a Controversial Entity. International Journal of Angiology. 2024;33(3):139-147.
13. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
14. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.